Published • loading... • Updated
Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma
Summary by Financial Post
6 Articles
6 Articles
+3 Reposted by 3 other sources
Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma
PARIS, FRANCE, 09 March 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik® (tazemetostat) in all indications from all Ipsen markets. Ipsen’s decision to withdraw is based on emerging data from the ongoing Phase…
As several key patents expire in 2028 and 2029, this choice illustrates the market's perceived weakness in Ipsen's ability to find new commercial relays.
Coverage Details
Total News Sources6
Leaning Left3Leaning Right1Center0Last UpdatedBias Distribution75% Left
Bias Distribution
- 75% of the sources lean Left
75% Left
L 75%
R 25%
Factuality
To view factuality data please Upgrade to Premium




